PBYI
PUMA BIOTECHNOLOGY, INC.
NASDAQ · Healthcare · Biotechnology · US
$10.21
+3.87%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$9.85
From 52W high−2.95%
Volume459347.00
Market cap$527.04M
P/E (TTM)19.0x
P/S (TTM)2.3x
Div yield—
Key dataOct 19, 2026
Open
$9.85
From 52W high
−2.95%
Volume
459347.00
Market cap
$527.04M
ValuationView details →
P/E (Fwd)
44.4x
EV/EBITDA
9.7x
P/E (TTM)
19.0x
RSI (14)
56.0
MomentumView details →
1D Return
+3.87%
YTD Return
+70.42%
SummaryUpdated Jun 1, 2026
Puma Biotechnology, Inc. (NASDAQ:PBYI) is a Los Angeles-based biopharmaceutical company founded in 2010 that focuses on developing and commercializing innovative cancer treatments. The company went public in 2012 and has established itself as a specialized oncology company with a primary focus on HER2-positive breast cancer therapies. Puma's flagship product is NERLYNX (neratinib), an oral medication approved for treating early-stage and advanced HER2-positive breast cancer patients. The company has built a global presence through licensing partnerships and continues to expand its pipeline through clinical development programs and potential in-licensing opportunities.
Similar companies
Latest newsMore news →
Puma Biotechnology initiated ALISCA-Lung2, a Phase II trial of alisertib in combination with paclitaxel for patients with advanced small cell lung cancer.32d agoPuma Biotech reported Q2 2026 earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share, and compared to $0.15 per share a year ago.74d ago